CoreBone News
4 articles
growth-positive
CoreBone Raises $3.7 Million Investment to Commercialize its Bioactive Bone Graft Material for Dental and Orthopedic Treatments & Expand Activity in China
CoreBone, a company that produces bioactive, coral-based bone graft material, has completed an investment round of $3.7 million. The Guangzhou Sino-Israel Biotech Investment Fund invested $3 million in CoreBones Chinese subsidiary, while The Trendlines Group and Agriline invested $700,000. The funds will be used to expand CoreBones global presence, particularly in China. CoreBone develops and sells bioactive bone graft material using cultured coral, eliminating the need for animal or human bone grafts. The investment will accelerate CoreBones sales efforts in China, where the import of foreign human-derived bone grafts is banned. The company aims to fulfill the growing demand for its products in the Chinese market.
Investment
growth-positive
Growing new bone from corals raised in the Israeli desert
Israeli company CoreBone has received CE approval to start selling its bone-graft product made of enhanced coral in Europe for dental and orthopedic procedures. The product is made from corals grown in a closed system using patented technology to provide bioactivity and eliminate biological contamination. CoreBones product offers the best of both worlds, combining the advantages of organic grafts and synthetic grafts. The global markets for orthopedic and dental bone-graft substitutes are expected to reach $3.4 billion and $1 billion, respectively, next year. CoreBones material has been found to have a high rate of bio-integration and connectivity with the host bone compared to leading products in the market. The company has raised about $2 million from public sources and private investors and is planning to launch its products in Europe and Israel.
Customers
growth-positive
Sci-Fi Medicine Sees Corals Turned Into Bone Grafts
Israeli company CoreBone is manufacturing bone grafts from coral grown in the desert for use in orthopedic and dental procedures. The company has developed a coral-based, bioactive bone graft that has all the qualities of a biological bone graft without the risk of contracting diseases. CoreBones bone grafts are expected to cost less than existing options in the orthopedic market. The company plans to begin human trials in selected hospitals in Israel and France before entering the market.
PartnersCustomers
growth-positive
CoreBone Implants Corals As Human Bone Replacements
CoreBone, a company that manufactures bone-replacements from corals, is experiencing growth in the market for bone replacements. The CEO, Ohad Schwartz, discovered the idea for using corals as bone substitutes and approached Professor Itzhak Binderman, who had already worked with corals for bone tissue building. CoreBone is growing corals in a controlled environment to ensure quality and is using a bioactive mineral diet to attract bone cells. The company has conducted successful animal trials and is planning to enter the dental market first, followed by the orthopedic market. They are seeking a $2.5 million investment to expand and develop products for these markets.
InvestmentExpand
